文献速递慢性静脉疾病

美国参保淋巴水肿患者疾病共病与治疗方式的相关性

Correlation of disease comorbidity with prescribed treatment among insured U.S. lymphedema patients.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2020-05-26

结果显示BCRL患者更多接受保守治疗,而PLEDU患者更多被处方简单气动压缩装置(SPCD),提示淋巴治疗在慢性静脉性肿胀及PLEDU防治中可能被低估。

要点

  • BCRL患者占全部研究患者的32.1%,占接受保守治疗者的41%。
  • PLEDU患者占全部研究患者的9.6%,但在PCD治疗组中占17.7%。
  • PLEDU患者占所有被处方SPCD的淋巴水肿患者的23.5%,BCRL患者仅占10.3%(P < .001)。

核心结论

  • BCRL与PLEDU患者的治疗方式存在明显差异。
  • 相较于BCRL患者,PLEDU患者较少接受保守治疗,更多被处方SPCD进行气动压缩治疗。
  • 这些差异提示淋巴治疗在慢性静脉性肿胀及PLEDU的预防和治疗中可能被低估。

研究设计与样本

  • 共纳入26,902例确诊淋巴水肿且索引日期前后12个月连续参保的患者,完整年份为2012年至2016年。
  • 患者被分为四类治疗:未治疗、保守治疗、简单PCD(SPCD)和高级PCD。
  • 淋巴水肿治疗与BCRL和PLEDU共病进行关联分析。

主要发现

  • BCRL患者占全部研究患者的32.1%,占接受保守治疗者的41%,占接受PCD治疗者的24%。
  • PLEDU患者占全部研究患者的9.6%,在保守治疗组中占7.8%,在PCD治疗组中占17.7%。
  • PLEDU患者占所有被处方SPCD的淋巴水肿患者的23.5%,BCRL患者占所有SPCD处方的10.3%(P < .001)。

临床怎么用

  • 临床应关注PLEDU患者接受保守淋巴治疗的比例偏低,评估其是否得到充分的综合消肿治疗。
  • 对PLEDU患者处方SPCD时,可结合保守治疗需求综合评估,避免单一依赖气动压缩。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to define the current forms of treatment in a contemporary population of lymphedema (LED) patients for LED related to breast cancer, the most prevalently diagnosed LED comorbidity in Western countries, and phlebolymphedema with venous leg ulcer (PLEDU), a sequela of chronic venous disease. The goals of LED therapy are to reduce edema, thereby improving function and related symptoms, and to improve skin integrity to prevent development of infection. Treatment is generally nonsurgical: conservative care, including complex physical therapy, manual lymphatic drainage, and compression bandaging; or pneumatic compression device (PCD) therapy by a simple nonprogrammable device or an advanced programmable device. METHODS: To determine the frequency of individual types of treatment for LED and their relationship to breast cancer-related lymphedema (BCRL) and PLEDU, we queried claims from a deidentified Health Insurance Portability and Accountability Act-compliant commercial administrative insurance database with >165 million members. A total of 26,902 patients identified with LED who had been enrolled with continuous medical benefits for 12 months before and after the index date for the complete years 2012 through 2016 were separated into four treatment categories: no treatment, conservative care, simple PCD (SPCD), and advanced PCD. LED treatment was related to the BCRL and PLEDU comorbidities. RESULTS: BCRL patients, who represented 32.1% of all study patients, made up 41% of all patients receiving conservative care and 24% of patients receiving PCD therapy. By contrast, PLEDU patients (9.6% of study patients) were proportionally under-represented in the conservative care group (7.8%) but composed a disproportionately high share of the PCD therapy group (17.7%). PLEDU patients represented 23.5% of all LED patients prescribed SPCD therapy, whereas BCRL patients composed 10.3% of total LED patient SPCD prescriptions (P < .001). CONCLUSIONS: Our analysis of a large health care administrative database showed clear differences between the way BCRL and PLEDU patients are treated. Compared with BCRL patients, PLEDU patients were less likely to receive conservative care and more likely to be prescribed SPCDs for pneumatic compression therapy. These differences suggest that lymphatic therapy may be undervalued for treatment of chronic venous swelling and prevention and treatment of PLEDU.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. O'Donnell TF, Izhakoff J, Gaebler JA, et al. Correlation of disease comorbidity with prescribed treatment among insured U.S. lymphedema patients. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32470618. doi:10.1016/j.jvsv.2020.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。